Ausgabe 1/2021
Inhalt (26 Artikel)
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)
Abeer H. Abdelhafez, Benjamin C. Musall, Beatriz E. Adrada, KennethR. Hess, Jong Bum Son, Ken-Pin Hwang, Rosalind P. Candelaria, Lumarie Santiago, Gary J. Whitman, Huong T. Le-Petross, Tanya W. Moseley, Elsa Arribas, Deanna L. Lane, Marion E. Scoggins, Jessica W. T. Leung, Hagar S. Mahmoud, Jason B. White, Elizabeth E. Ravenberg, Jennifer K. Litton, Vicente Valero, Peng Wei, Alastair M. Thompson, Stacy L. Moulder, Mark D. Pagel, Jingfei Ma, Wei T. Yang, Gaiane M. Rauch
Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire
Santosh K. Somasundaram, Shelley Potter, Suzanne Elgammal, Anthony J. Maxwell, Amtul S. Sami, Sue K. Down, Rajiv V. Dave, James Harvey
Width of margins in phyllodes tumors of the breast: the controversy drags on?—a systematic review and meta-analysis
Arnaud Toussaint, Romain Piaget-Rossel, Coraline Stormacq, Patrice Mathevet, Karine Lepigeon, Patrick Taffé
Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer
Yuxiang Lin, Ling Lin, Fangmeng Fu, Chuan Wang, Anqi Hu, Juanjuan Xie, Meichen Jiang, Zhenxin Wang, Lujie Yang, Rongrong Guo, Pengyuan Yang, Huali Shen
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients
Miryam Yusufov, Margo Nathan, Aleta Wiley, Julia Russell, Ann Partridge, Hadine Joffe
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
Satu Tiainen, Kirsi Rilla, Kirsi Hämäläinen, Sanna Oikari, Päivi Auvinen
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer
Lei Xue, Fengju Chen, Fei Yue, Laura Camacho, Sushma Kothapalli, Guanyun Wei, Shixia Huang, Qianxing Mo, Fei Ma, Yi Li, Sao Jiralerspong
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment
Jiehui Deng, Aatish Thennavan, Suhagi Shah, Ece Bagdatlioglu, Natalie Klar, Adriana Heguy, Christian Marier, Peter Meyn, Yutong Zhang, Kristen Labbe, Christina Almonte, Michelle Krogsgaard, Charles M. Perou, Kwok-Kin Wong, Sylvia Adams
Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer
Zahra Mohamadzade, Frouzande Mahjoubi, Bahram M. Soltani
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A. Korde, Florentine Hilbers, Christian Jackisch, Olena Werner, Richard D. Gelber, Aminah Jatoi, Amylou C. Dueck, Alvaro Moreno-Aspitia, Christos Sotiriou, Evandro de Azambuja, Martine Piccart
Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia
Alem Gebremariam, Nebiyu Dereje, Adamu Addissie, Alemayehu Worku, Mathewos Assefa, Aynalem Abreha, Wondemagegnehu Tigeneh, Lydia E. Pace, Eva Johanna Kantelhardt, Ahmedin Jemal
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
Masato Takahashi, Shoichiro Ohtani, Shigenori E. Nagai, Seiki Takashima, Miki Yamaguchi, Michiko Tsuneizumi, Yoshifumi Komoike, Tomofumi Osako, Yoshinori Ito, Masahiko Ikeda, Kazushige Ishida, Takahiro Nakayama, Tsutomu Takashima, Takashi Asakawa, Sho Matsumoto, Daisuke Shimizu, Norikazu Masuda
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
Otto Metzger Filho, Anita Giobbie-Hurder, Nancy U. Lin, Meredith Faggen, Steven Come, Thomas Openshaw, Michael Constantine, Jeanna Walsh, Rachel A. Freedman, Bryan Schneider, Harold J. Burstein, Erica L. Mayer
FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact
Marianne Vogsen, Jeanette Dupont Jensen, Ivar Yannick Christensen, Oke Gerke, Anne Marie Bak Jylling, Lisbet Brønsro Larsen, Poul-Erik Braad, Katrine Lydolph Søe, Camilla Bille, Marianne Ewertz, Malene Grubbe Hildebrandt
Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis
Soo Yeon Baek, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sei-Hyun Ahn, Sae Byul Lee
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
Shari B. Goldfarb, Volkan Turan, Giuliano Bedoschi, Enes Taylan, Nadia Abdo, Tessa Cigler, Heejung Bang, Sujita Patil, Maura N. Dickler, Kutluk H. Oktay
Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan
Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
Elisa Van Raemdonck, G. Floris, P. Berteloot, A. Laenen, I. Vergote, H. Wildiers, K. Punie, P. Neven
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling
Gregory S. Calip, John Kidd, Ryan Bernhisel, Hannah C. Cox, Jennifer Saam, Garth H. Rauscher, Johnathan M. Lancaster, Kent F. Hoskins
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study
Judy N. Jacobse, Michael Schaapveld, Naomi B. Boekel, Maartje J. Hooning, Agnes Jager, Margreet H. A. Baaijens, Michael Hauptmann, Nicola S. Russell, Emiel J. T. Rutgers, Berthe M. P. Aleman, Gabe S. Sonke, Flora E. van Leeuwen
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
Katya Losk, Rachel A. Freedman, Alison Laws, Olga Kantor, Elizabeth A. Mittendorf, Zhenying Tan-Wasielewski, Lorenzo Trippa, Nancy U. Lin, Eric P. Winer, Tari A. King
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
Hannah Grace Abraham, Yaoxuan Xia, Bhramar Mukherjee, Sofia Diana Merajver
Impact of patients’ refusal to undergo adjuvant treatment measures on survival
H. Männle, J. W. Siebers, F. Momm, K. Münstedt
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors
Pietro Sollena, Vasiliki Nikolaou, Nikolaos Soupos, Elias Kotteas, Dimitra Voudouri, Alexandros J. Stratigos, Davide Fattore, Maria Carmela Annunziata, Armando Orlandi, Lucia Di Nardo, Zoe Apalla, Florian Deilhes, Maria Concetta Romano, Gabriella Fabbrocini, Vincent Sibaud, Ketty Peris
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
Michela Palleschi, Emanuela Scarpi, Chiara Casadei
Telerehabilitation for patients with breast cancer through the COVID-19 pandemic
Laura Ferreira de Rezende, Vinícius Emanoel Francisco, Ricardo Laier Franco